INDIANAPOLIS, July 27, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study data monitoring committee to continue the Phase 3 trial of the investigational medicine evacetrapib, based on data from an interim futility analysis.
Last patient visit in ACCELERATE - which is evaluating evacetrapib in approximately 12,000 patients with high-risk atherosclerotic cardiovascular disease (ASCVD) - is expected in July 2016.
Lilly Provides Update on Evacetrapib Phase 3 Trial (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.